HC Wainwright Analysts Decrease Earnings Estimates for AVDL

Avadel Pharmaceuticals plc (NASDAQ:AVDL) – Stock analysts at HC Wainwright decreased their FY2027 earnings per share (EPS) estimates for shares of Avadel Pharmaceuticals in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst O. Livnat now anticipates that the company will post earnings of $1.67 per share for the year, down from their prior forecast of $1.74. HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Avadel Pharmaceuticals’ current full-year earnings is ($0.50) per share. HC Wainwright also issued estimates for Avadel Pharmaceuticals’ FY2028 earnings at $1.88 EPS.

Avadel Pharmaceuticals (NASDAQ:AVDL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.03. The business had revenue of $50.00 million during the quarter, compared to analyst estimates of $48.43 million. Avadel Pharmaceuticals had a negative net margin of 52.53% and a negative return on equity of 93.34%. The company’s revenue was up 624.6% on a year-over-year basis. During the same period in the prior year, the business posted ($0.41) earnings per share.

Several other equities analysts also recently commented on the company. Oppenheimer boosted their price objective on Avadel Pharmaceuticals from $29.00 to $30.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Needham & Company LLC restated a “buy” rating and issued a $22.00 price target on shares of Avadel Pharmaceuticals in a research note on Tuesday. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Avadel Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $24.43.

Avadel Pharmaceuticals Stock Performance

Shares of Avadel Pharmaceuticals stock opened at $10.91 on Thursday. Avadel Pharmaceuticals has a fifty-two week low of $10.39 and a fifty-two week high of $19.09. The company has a market capitalization of $1.05 billion, a P/E ratio of -13.81 and a beta of 1.47. The company has a fifty day moving average of $13.49 and a 200 day moving average of $15.02.

Institutional Investors Weigh In On Avadel Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the company. FMR LLC purchased a new stake in Avadel Pharmaceuticals during the third quarter valued at $31,000. Amalgamated Bank bought a new stake in shares of Avadel Pharmaceuticals in the 2nd quarter worth about $45,000. Quarry LP purchased a new stake in shares of Avadel Pharmaceuticals during the 2nd quarter valued at about $63,000. BNP Paribas Financial Markets lifted its holdings in shares of Avadel Pharmaceuticals by 60.5% in the 1st quarter. BNP Paribas Financial Markets now owns 4,469 shares of the company’s stock valued at $75,000 after acquiring an additional 1,685 shares during the last quarter. Finally, Advisors Asset Management Inc. lifted its holdings in shares of Avadel Pharmaceuticals by 56.1% in the 3rd quarter. Advisors Asset Management Inc. now owns 7,921 shares of the company’s stock valued at $104,000 after acquiring an additional 2,846 shares during the last quarter. 69.19% of the stock is currently owned by hedge funds and other institutional investors.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.